## CNC: Centene Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.7% below STRENGTH zone (4.0-10.0%); PEG 1.56 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($35.38)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Centene Corporation $CNC Shares Acquired by Amundi**
- Source: MarketBeat | 20251207T081924 | Somewhat-Bullish | Relevance: 98%
-  Amundi has increased its stake in Centene Corporation (NYSE:CNC) by 6.2% during the 2nd quarter, now owning 3,384,752 shares valued at $183,724,000. Several other hedge funds also adjusted their positions in Centene, and institutional investors and hedge funds collectively own 93.63% of the stock. Analyst ratings for Centene are mixed, with a consensus "Hold" rating and an average price target of $40.00.

**2. Sarah London: 100 Most Influential People in Healthcare 2025**
- Source: Modern Healthcare | 20251208T170810 | Bullish | Relevance: 98%
-  Sarah London, the CEO of Centene Corp., has been recognized as one of the "100 Most Influential People in Healthcare 2025" by Modern Healthcare. She is listed as #22 on this prestigious list.

**3. Norges Bank Makes New $32.16 Million Investment in Crane NXT, Co. $CXT**
- Source: MarketBeat | 20251208T111001 | Somewhat-Bullish | Relevance: 57%
-  Norges Bank has made a new investment of $32.16 million in Crane NXT, Co. (NYSE:CXT), acquiring 596,709 shares and owning approximately 1.04% of the company. Other institutional investors like Ameriprise, Wellington, and Congress Asset Management also increased their stakes. Analysts currently have a "Hold" rating on CXT with an average price target of $74.25.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | Bernstein | $45 | $36 | +25% |
| 2025-11-12 | Wells Fargo | $35 | $41 | -15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | Bernstein | main | Outperform |
| 2025-11-12 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 2 ($2.58M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.6% (-2.8%)
- Blackrock Inc.: 9.2% (+0.3%)
- State Street Corpora: 4.3% (-7.7%)
- AQR Capital Manageme: 3.0% (+76.6%)
- Geode Capital Manage: 2.6% (-4.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.2% 5d) with bearish MACD, trend may be turning.
2. Long-term trend broken: trading 13.9% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.56 elevated, pricing in significant growth expectations. Forward P/E 13.0x attractive for 46% earnings growth. Balance sheet: $1.1B free cash flow. Insider selling cluster ($2.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.7B |
| Beta | 0.48 |
| 52W Range | $25.08 - $66.81 |
| Short Interest | 3.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.56 |
| Forward P/E | 13.0 |
| Current P/E | 19.1 |
| YoY Growth | 46.3% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 2.5% to -0.7% (-3.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.7pp (needs >4.0% for momentum thesis). Outperforming sector by 3.8pp, stock-specific strength. Below SMA200 (0.86x), long-term trend not supportive. RSI neutral at 54.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.69% (CS: 55) | Neutral |
| RSI_14 | 53.9 | Neutral |
| MACD Histogram | -0.05 | Bearish |
| vs SMA20 | 1.015x | Above |
| vs SMA50 | 1.039x | Above |
| vs SMA200 | 0.861x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $38.08
- **Stop Loss:** $35.38 (7.1% risk)
- **Target:** $40.78 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 111
- **Position Value:** $4,226.88
- **Portfolio %:** 4.23%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-03 (Est: $-1.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $0.50 | +404.3% |
| 2025Q2 | $0.21 | $-0.16 | -177.3% |
| 2025Q1 | $2.52 | $2.90 | +15.3% |
| 2024Q4 | $0.49 | $0.80 | +62.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*